Shilpa Medicare’s JV Oncosol gets USFDA approval for IMKELDI

Shilpa Medicare’s Joint Venture Oncosol (50:50 JV with Liqmeds Lifecare Limited, a Zydus group company and Koana Healthcare Limited, Shilpa Medicare group company) along with its partner Shorla Oncology announces that the USFDA has approved IMKELDI (imatinib oral solution), the first oral liquid form of imatinib to treat certain forms of leukemia and other cancers.

IMKELDI is an advanced liquid formulation of imatinib designed to provide dosing accuracy. IMKELDI can help slow or prevent the growth of specific cancers, including chronic myeloid leukemia (CML) and acute lymphoblastic leukemia, myelodysplastic syndrome /myeloproliferative disease (MDS/MPD), and gastrointestinal tumors (GIST).

In 2024, an estimated 9,280 people will be diagnosed with CML1, over 10,000 with MDS/MPD2, and up to 6,000 with GIST3 in the U.S. Despite the proven clinical benefits of imatinib, patient adherence can be an issue,4,5 underscoring a critical unmet need for a more accessible, patient-friendly oral solution delivery system.

Shilpa Medicare Limited, headquartered at Raichur, Karnataka, India, is a vertically integrated, manufacturer and distributor of quality drugs to global markets; specializing in the Oncology therapeutic segment and introducing novel drugs focusing on patient convenience and compliance.

Shares of Shilpa Medicare Limited was last trading in BSE at Rs. 893.10 as compared to the previous close of Rs. 888.80. The total number of shares traded during the day was 27136 in over 1374 trades.

The stock hit an intraday high of Rs. 907.65 and intraday low of 880.45. The net turnover during the day was Rs. 24236124.00.

Source : Equity Bulls

Keywords

ShilpaMedicare INE790G01031 JV Oncosol LiqmedsLifecare ShorlaOncology USFDA Approval IMKELDI imatinib oralsolution